Medicine and Health

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease

A. Rastogi and J. L. J. Jr

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are revolutionizing the management of cardiovascular and renal health, showcasing significant benefits for patients with heart failure and chronic kidney disease, irrespective of diabetes status. Discover the extensive mechanisms behind these remarkable outcomes in the research conducted by A Rastogi and James L Januzzi Jr.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

J. F. E. Mann, P. Rossing, et al.

Medicine and Health

Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease

N. Snelder, R. Heinig, et al.

Medicine and Health

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

H. M. Colhoun, I. Lingvay, et al.

Medicine and Health

Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial

A. Podadera-herreros, A. P. A. Larriva, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny